Michael R. Ehrenstein

5 University Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Elevated ferritin as a companion biomarker of myeloid-driven inflammation in RNP/Sm co-positive, treatment-resistant SLE endotype.

Elevated ferritin as a companion biomarker of myeloid-driven inflammation in RNP/Sm co-positive, treatment-resistant SLE endotype.

Journal: bioRxiv : the preprint server for biology

Published: February 23, 2026

Revisiting safety and refining benefit of rituximab-belimumab combination for refractory SLE.

Revisiting safety and refining benefit of rituximab-belimumab combination for refractory SLE.

Journal: The Lancet. Rheumatology

Published: July 01, 2025

IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus.

IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus.

Journal: Cell reports. Medicine

Published: January 08, 2025

Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.

Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.

Journal: The Lancet. Rheumatology

Published: July 02, 2024

Differences in management approaches for lupus nephritis within the UK.

Differences in management approaches for lupus nephritis within the UK.

Journal: Rheumatology advances in practice

Published: October 21, 2023

SLE is not a one-size-fits-all disease.

SLE is not a one-size-fits-all disease.

Journal: The Journal of experimental medicine

Published: April 25, 2023

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.

Journal: The Lancet. Rheumatology

Published: April 03, 2023

Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial.

Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial.

Journal: The Lancet. Rheumatology

Published: February 09, 2023

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease.

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease.

Journal: BMC medicine

Published: September 06, 2022

Author Correction: A novel Streptococcus pneumoniae human challenge model demonstrates Treg lymphocyte recruitment to the infection site.

Author Correction: A novel Streptococcus pneumoniae human challenge model demonstrates Treg lymphocyte recruitment to the infection site.

Journal: Scientific reports

Published: April 06, 2022

Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis.

Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis.

Journal: Rheumatology (Oxford, England)

Published: February 24, 2022

Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.

Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.

Journal: Rheumatology (Oxford, England)

Published: February 04, 2022

Showing 1-12 of 51

Last Updated: 09/26/2026